1 March 2022 - The March 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes a few revised listings:

• Eculizumab (Soliris) - new PBS medicine (transfer from LSDP)
• Etanercept (Enbrel) - new formulation
• Gemtuzumab ozogamicin (Mylotarg) - new medicine
• Methoxsalen (Uvadex) - new indication
• Molnupiravir (Lagevrio) - new medicine
• Ravulizumab (Ultomiris) - new medicine
• Zanubrutinib (Brukinsa) - new medicine

Read Summary of PBS Changes